1
|
Ratih R, Asmari M, Abdel-Megied AM, Elbarbry F, El Deeb S. Biosimilars: Review of regulatory, manufacturing, analytical aspects and beyond. Microchem J 2021. [DOI: 10.1016/j.microc.2021.106143] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
2
|
Alsamil AM, Giezen TJ, Egberts TC, Leufkens HG, Vulto AG, van der Plas MR, Gardarsdottir H. Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review. Eur J Pharm Sci 2020; 154:105501. [DOI: 10.1016/j.ejps.2020.105501] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2020] [Revised: 07/29/2020] [Accepted: 07/29/2020] [Indexed: 12/13/2022]
|
3
|
Tani J, Ito Y, Tatemichi S, Yamakami M, Fukui T, Hatano Y, Kakimoto S, Kotani A, Sugimura A, Mihara K, Yamamoto R, Tanaka N, Minami K, Takahashi K, Hirato T. Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa. PLoS One 2020; 15:e0231830. [PMID: 32302352 PMCID: PMC7164597 DOI: 10.1371/journal.pone.0231830] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2019] [Accepted: 04/01/2020] [Indexed: 12/02/2022] Open
Abstract
Renal anemia is predominantly caused by a relative deficiency in erythropoietin (EPO). Conventional treatment for renal anemia includes the use of recombinant human EPO (rhEPO) or a long-acting erythropoiesis-activating agent named darbepoetin alfa, which is a modified rhEPO with a carbohydrate chain structure that differs from native hEPO. We have developed a biosimilar to darbepoetin alfa designated JR-131. Here, we comprehensively compare the physicochemical and biological characteristics of JR-131 to darbepoetin alfa. JR-131 demonstrated similar protein structure to the originator, darbepoetin alfa, by peptide mapping and circular dichroism spectroscopy. Additionally, mass spectroscopic analyses and capillary zone electrophoresis revealed similar glycosylation patterns between the two products. Human bone marrow-derived erythroblasts differentiated and proliferated to form colonies with JR-131 to a similar degree as darbepoetin alfa. Finally, JR-131 stimulated erythropoiesis and improved anemia in rats similarly to darbepoetin alfa. Our data show the similarity in physicochemical and biological properties of JR-131 to those of darbepoetin alfa, and JR-131 therefore represents a biosimilar for use in the treatment of renal anemia.
Collapse
Affiliation(s)
- Junya Tani
- Research Division, JCR Pharmaceuticals Co., Ltd., Kobe, Japan
| | - Yae Ito
- Research Division, JCR Pharmaceuticals Co., Ltd., Kobe, Japan
| | | | - Makoto Yamakami
- Research Division, JCR Pharmaceuticals Co., Ltd., Kobe, Japan
| | - Tsuyoshi Fukui
- Research Division, JCR Pharmaceuticals Co., Ltd., Kobe, Japan
| | - Yukichi Hatano
- Research Division, JCR Pharmaceuticals Co., Ltd., Kobe, Japan
| | - Shinji Kakimoto
- Research Planning Division, JCR Pharmaceuticals Co., Ltd., Kobe, Japan
| | - Ayaka Kotani
- Research Planning Division, JCR Pharmaceuticals Co., Ltd., Kobe, Japan
| | | | - Kazutoshi Mihara
- Research Division, JCR Pharmaceuticals Co., Ltd., Kobe, Japan
- * E-mail: (KM); (KM)
| | - Ryuji Yamamoto
- Research Division, JCR Pharmaceuticals Co., Ltd., Kobe, Japan
| | - Noboru Tanaka
- Research Division, JCR Pharmaceuticals Co., Ltd., Kobe, Japan
| | - Kohtaro Minami
- Research Division, JCR Pharmaceuticals Co., Ltd., Kobe, Japan
- * E-mail: (KM); (KM)
| | | | - Tohru Hirato
- Research Division, JCR Pharmaceuticals Co., Ltd., Kobe, Japan
| |
Collapse
|